| urea |
drug |
3 |
2 |
urea-containing buffer |
| urine |
drug |
3 |
— |
|
| US |
cohort |
3 |
3 |
United States |
| USA |
cohort |
6 |
4 |
U.S.A., United States |
| US adults 2012-2013 |
cohort |
2 |
2 |
US adults (2012–2013), US adults 2012–2013, US adults reported past year drinking 2012-2013, United States adults 2012-2013 |
| U.S. children |
cohort |
2 |
2 |
American children, U.S. children, United States children, children in the United States |
| U.S. Department of Veterans Affairs |
cohort |
2 |
1 |
VA |
| users |
cohort |
4 |
2 |
MJ+ALC users, cannabis users, substance users |
| US population |
cohort |
4 |
2 |
United States population |
| valence |
phenotype |
2 |
2 |
loss/gain, win>avoid loss |
| validation sample |
cohort |
3 |
1 |
hold out sample, validation sample |
| Valproic acid |
drug |
7 |
4 |
VPA, Val, Val dose, valproate, valproic acid |
| variant |
cohort |
32 |
12 |
SNPs, directly-typed variant, genetic variant, genetic variants, imputed variant, n, variant, variants |
| vascular disease |
phenotype |
5 |
3 |
|
| vasopressin |
drug |
7 |
5 |
AVP, antidiuretic hormone, vasopressin |
| VATSPSUD |
cohort |
3 |
2 |
|
| Velocardiofacial syndrome |
phenotype |
3 |
1 |
VCFS |
| Ventricular enlargement |
phenotype |
2 |
2 |
ventricular size, ventricular size increase |
| verbal fluency |
phenotype |
6 |
4 |
poorer verbal fluency production, verbal fluency |
| verbal learning |
phenotype |
5 |
1 |
|
